Livoletide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Livoletide
Accession Number
DB15188
Type
Small Molecule
Groups
Investigational
Description

Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).

Structure
Thumb
Synonyms
  • Livoletide
  • Livolétide
  • Livoletidum
External IDs
AZP 531 / AZP-531
Categories
Not Available
UNII
9VHD7J6363
CAS number
1088543-62-7
Weight
Average: 962.036
Monoisotopic: 961.472977149
Chemical Formula
C40H63N15O13
InChI Key
JXPWLIYXIWGWSA-CLBRJLNISA-N
InChI
InChI=1S/C40H63N15O13/c1-19(2)31-38(67)51-23(8-11-29(42)58)34(63)53-26(17-56)39(68)55-14-4-6-27(55)37(66)50-24(9-12-30(59)60)33(62)52-25(15-20-16-45-18-47-20)36(65)49-22(7-10-28(41)57)32(61)48-21(35(64)54-31)5-3-13-46-40(43)44/h16,18-19,21-27,31,56H,3-15,17H2,1-2H3,(H2,41,57)(H2,42,58)(H,45,47)(H,48,61)(H,49,65)(H,50,66)(H,51,67)(H,52,62)(H,53,63)(H,54,64)(H,59,60)(H4,43,44,46)/t21-,22-,23-,24-,25-,26-,27-,31-/m0/s1
IUPAC Name
3-[(3S,6S,9S,12S,15S,18S,21S,26aS)-12-(3-carbamimidamidopropyl)-9,18-bis(2-carbamoylethyl)-21-(hydroxymethyl)-6-[(1H-imidazol-5-yl)methyl]-1,4,7,10,13,16,19,22-octaoxo-15-(propan-2-yl)-hexacosahydropyrrolo[1,2-a]1,4,7,10,13,16,19,22-octaazacyclotetracosan-3-yl]propanoic acid
SMILES
[H][C@@]12CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(O)=O)NC2=O)C(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
28528452
ChEMBL
CHEMBL2029605

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
2, 3TerminatedTreatmentHyperphagia / Prader-Willi Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.2 mg/mLALOGPS
logP-2.4ALOGPS
logP-10ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)3.51ChemAxon
pKa (Strongest Basic)11.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count15ChemAxon
Polar Surface Area458.3 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity243.61 m3·mol-1ChemAxon
Polarizability95.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:57 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates